ÍøºìºÚÁÏ

Skip to main content
(352) 273-8740

Ali Ataya, MD : Research

Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)

Photo of Ali Ataya
(352) 273-8740 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Dyspnea , 10 publications
  • Pulmonary Alveolar Proteinosis , 4 publications
  • Lymphangioleiomyomatosis , 4 publications
  • Fever , 4 publications

Research activity

122 publications

396 citations

Why is this important?

Active clinical trials

Prosera

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - 75 Years
Sexes
All
Hemotag
Investigator
Ali Ataya
Status
Accepting Candidates
ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator
Ali Ataya
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

122 publications

2025

Silastic Septal Splints in the Management of Refractory Epistaxis in Hereditary Hemorrhagic Telangiectasia.

International forum of allergy & rhinology

•

2025

Sirolimus Use During Pregnancy in Women with Lymphangioleiomyomatosis

Annals of the American Thoracic Society

2025

Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy

Journal of Thrombosis and Haemostasis

2025

Temporary Transvenous Diaphragm Neurostimulation for Weaning from Mechanical Ventilation (RESCUE-3)

American Journal of Respiratory and Critical Care Medicine

2025

The healthcare burden of pulmonary alveolar proteinosis (PAP).

Orphanet journal of rare diseases

•